Phaseline

Companies › NiKang Therapeutics

NiKang Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NKT5097
CDK2/CDK4 dual degrader
CDK2, CDK4Phase 1HR+ Breast CancerJul 2027
NKT3964
CDK2 Degrader
CDK2Phase 1Solid TumorJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07029399NKT5097Phase 1HR+ Breast CancerOncologyJul 2027
NCT06586957NKT3964Phase 1Solid TumorOncologyJan 2029

Targets

CDK2 (2) CDK4 (1)

Companies with the same targets

Pfizer Avenzo Therapeutics Chia Tai Tianqing Pharmaceutical Group AstraZeneca BeiGene Eilean Therapeutics Incyclix Bio Novartis Pharmacosmos BeOne Medicines

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.